Dr Reddy’s Laboratories Ltd and Bayer have entered into a partnership to market and distribute a second brand of Vericiguat in India. Under the terms of this agreement, Bayer has granted non-exclusive rights to Dr Reddy’s under the brand name Gantra.
Vericiguat is a medication used to reduce the risk of cardiovascular death and hospitalisation in certain patients with heart failure after a recent acute decompensation event. India has between 8-10 million people with heart failure, making it one of the largest populations with this condition.
Shweta Rai, Managing Director, Bayer Zydus Pharma and Country Division Head (CDH) for Bayer’s Pharmaceuticals Business in South Asia said, “Despite therapy, chronic heart failure patients can experience disease progression that disrupts their lives and leads to worsening heart failure events. Vericiguat can help slow down disease progression, reduce hospital admissions and improve their chances of survival. This partnership with Dr Reddy’s presents in improving health outcomes for patients with chronic heart failure, following a recent event of worsening heart failure.”
MV Ramana, CEO-Branded Markets (India and Emerging Markets), Dr Reddy’s, said: “Strengthening our chronic therapy portfolio in India continues to be a focus area for us. Vericiguat is a first-in-class sGC stimulator indicated for adults with symptomatic, chronic heart failure and ejection fraction less than 45 per cent following worsening heart failure.”
